Humacyte Financials
| HUMA Stock | USD 4.51 0.14 3.01% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.29 | 4.5154 |
|
|
The financial analysis of Humacyte is a critical element in measuring its lifeblood. Investors should not minimize Humacyte's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Humacyte | Select Account or Indicator |
Understanding current and past Humacyte Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Humacyte's financial statements are interrelated, with each one affecting the others. For example, an increase in Humacyte's assets may result in an increase in income on the income statement.
Please note, the presentation of Humacyte's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Humacyte's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Humacyte's management manipulating its earnings.
Humacyte Stock Summary
Humacyte competes with Crinetics Pharmaceuticals, Viridian Therapeutics, Cytokinetics, Structure Therapeutics, and Immunocore Holdings. Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. Humacyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US44486Q1031 |
| CUSIP | 44486Q103 020751103 |
| Location | North Carolina; U.S.A |
| Business Address | 2525 East North |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.humacyte.com |
| Phone | 919 313 9633 |
| Currency | USD - US Dollar |
Humacyte Key Financial Ratios
| Return On Equity | -8.51 | ||||
| Price To Sales | 153.91 X | ||||
| Gross Profit | 1.56 M | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) |
Humacyte Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Humacyte's current stock value. Our valuation model uses many indicators to compare Humacyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Humacyte competition to find correlations between indicators driving Humacyte's intrinsic value. More Info.Humacyte is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Humacyte's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Humacyte's earnings, one of the primary drivers of an investment's value.Humacyte Systematic Risk
Humacyte's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Humacyte volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Humacyte correlated with the market. If Beta is less than 0 Humacyte generally moves in the opposite direction as compared to the market. If Humacyte Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Humacyte is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Humacyte is generally in the same direction as the market. If Beta > 1 Humacyte moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Humacyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Humacyte's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Humacyte growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Humacyte December 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Humacyte help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Humacyte. We use our internally-developed statistical techniques to arrive at the intrinsic value of Humacyte based on widely used predictive technical indicators. In general, we focus on analyzing Humacyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Humacyte's daily price indicators and compare them against related drivers.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 33.89 | |||
| Value At Risk | (10.78) | |||
| Potential Upside | 7.57 |
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |